Tafamidis ATTR denied as non-formulary by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Tafamidis as Non-Formulary

Aetna's formulary — its list of covered drugs — is tiered by cost and clinical priority. Tafamidis may sit on a restricted tier, require separate authorization, or in some plan designs be entirely excluded from the formulary. A non-formulary denial does not mean the drug is medically inappropriate or that coverage is impossible; it means the plan's default drug list does not include it without additional steps. Patients with ATTR cardiomyopathy frequently succeed on appeal because there is no therapeutically equivalent formulary alternative — the condition is progressive and the treatment is disease-specific.

## Your Federal Appeal Rights

• ACA §2719 External Review: After exhausting Aetna's internal appeal process (typically two internal levels), you may request an independent external review. The window is generally approximately four months from your final denial — confirm the exact date on your denial notice.
• ERISA §503: Employer-plan members are entitled to a written explanation of why the formulary exclusion applies and a full-and-fair review of any exception request.
• Expedited Track: Available if delay would seriously jeopardize your health; simultaneous internal/external review requests are permitted.

## Concrete Appeal Steps and Timeline

1. Request a formulary exception — this is a separate, often faster pathway than a standard appeal. Aetna's formulary exception process requires a prescriber attestation that no formulary alternative is medically appropriate. 2. Obtain Aetna's coverage policy for tafamidis and its formulary exception criteria. 3. If the exception is denied, file a formal Level 1 internal appeal citing the absence of a clinically equivalent alternative. 4. If upheld, escalate to Level 2 and then to external IRO review within the deadline on the denial.

## Documentation to Gather

• Formulary alternative review: a prescriber statement explaining why each formulary-listed cardiac drug is not an equivalent substitute for tafamidis in ATTR-CM (the mechanism of action is unique to this drug class).
• Diagnosis confirmation: imaging or biopsy confirming ATTR-CM, genetic subtype if relevant.
• Clinical necessity letter: prescriber's explanation of the disease's progressive nature and the urgency of disease-modifying treatment.
• Guideline reference: generic citation to relevant ACC/AHA or Heart Failure Society of America (HFSA) guidelines supporting tafamidis in this indication — your cardiologist should provide this language.

## Criteria-Mapping Structure

Aetna's formulary exception form typically asks the prescriber to document the diagnosis, why formulary alternatives are contraindicated or clinically inappropriate, and why the requested drug is medically necessary. Prepare a one-page chart: column one lists each formulary alternative Aetna identifies; column two provides the specific clinical reason it is not appropriate for this patient. Attach the diagnosis confirmation and the prescriber letter. Completeness at submission significantly reduces the likelihood of a second denial.